Skip to Content


In the US, Vorinostat (vorinostat systemic) is a member of the drug class histone deacetylase inhibitors and is used to treat Cutaneous T-cell Lymphoma.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Deacetylase inhibitor

Chemical Names

N-hydroxy-N'-phenyloctanediamide (WHO)


Octandisäure hydroxyamid phenylamid (IUPAC)

Octanediamide, N-hydroxy-N'-phenyl-

Suberoylanilide hydroxamic acid

Foreign Names

  • Vorinostatum (Latin)
  • Vorinostat (German)
  • Vorinostat (French)
  • Vorinostat (Spanish)

Generic Names

  • Vorinostat (OS: USAN, JAN)
  • CCRIS 8456 (IS)
  • MK-0683 (IS: Merck)
  • SAHA (IS)
  • SAHA cpd (IS)

Brand Names

  • Zolinza
    Merck, Canada; Merck, United States; Merck Sharp & Dohme, Chile; Merck Sharp & Dohme, Colombia; Merck Sharp & Dohme, Latvia; Merck Sharp & Dohme, Mexico; Merck Sharp & Dohme Pharmaceuticals, Russian Federation; MSD, Argentina; MSD, Japan


IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.